View Post

ADCs in Breast Cancer: Shaping the Future of HER2– and TROP2-Targeted Therapy

In In The News by Barbara Jacoby

By: Alexandra Gerlach From: pharmacytimes.com Key Takeaways ADCs target specific tumor antigens, enhancing therapeutic windows and efficacy, with HER2 and TROP-2 as key targets in breast cancer. HER2-targeting ADCs, T-DM1 and T-DXd, have shown significant benefits in early and metastatic breast cancer, improving survival and response rates. TROP-2-targeting ADCs, SG and Dato-DXd, are approved for metastatic breast cancer, showing efficacy …